✦ LIBER ✦

Treatment of glucocorticoid-resistant or relapsing takayasu arteritis with methotrexate

✍ Scribed by Gary S. Hoffman; Randi Y. Leavitt; Gail S. Kerr; Menachem Rottem; Michael C. Sneller; Anthony S. Fauci

Book ID: 101648993
Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 465 KB
Volume: 37
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.1780370420

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Filtration Leukocytapheresis Therapy in

Filtration Leukocytapheresis Therapy in the Treatment of Rheumatoid Arthritis Patients Resistant To or Failed with Methotrexate

✍ Kazuo Kempe; Hiroshi Tsuda; Kwangseok Yang; Ken Yamaji; Yoshinori Kanai; Hiroshi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

PAR1 PHARMACOECONOMIC ANALISIS OF THE TR

PAR1 PHARMACOECONOMIC ANALISIS OF THE TREATMENT WITH LEFLUNOMIDEMETHOTREXATE OR INFLIXIMABMETHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS RESISTANT TO METHOTREXATE

✍ C Rubio Terrés; F Romero; A Burrell; A Domínguez-Gil 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Treatment of primary resistant or relaps

Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor

✍ David P. Schenkein; Yener Koc; Thierry Alcindor; Edward A. Stadtmauer; Kenneth B 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 210 KB

A multicentre phase II trial of gemcitab

A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03

✍ F. Hitz; G. Martinelli; E. Zucca; R. von Moos; W. Mingrone; M. Simcock; J. Peter 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Abstract Mantle cell lymphoma (MCL) has a poor prognosis with often short and incomplete remissions. We aimed to test the efficacy and tolerability of gemcitabine in treating MCL. Gemcitabine was given in doses of 1000 mg/m^2^ as a 30 min infusion on days 1 and 8 of each 3 week cycle for a maxim